Literature DB >> 2500767

Characterization of the mononuclear infiltrate in Bowen's disease (squamous cell carcinoma in situ). Evidence for a T cell-mediated anti-tumour immune response.

J M Habets1, B Tank, T van Joost.   

Abstract

We investigated the dermal inflammatory infiltrate and the expression of HLA-DR and beta 2-microglobulin on the tumour cells in 8 Bowen's disease (BD) using a series of monoclonal antibodies. The inflammatory infiltrate was classified as mild, moderate or heavy. The infiltrate in all cases consisted mainly of T cells (55 +/- 21%) and where the T helper (TH) subset predominated over the T suppressor/cytotoxic (TS/C) subset (TH/TS/C ratio of 2.4 +/- 1.0). The mean percentage of HLA-DR positive cells was 58 +/- 18%, Langerhans cells (LC) 4 +/- 1% and Leu-M5 positive cells (monocytes/macrophages) 9 +/- 2%. The mean percentage of B cells and natural killer (NK) cells was 4 +/- 5% and 1 +/- 2% respectively. B cells and NK cells did not invade any of the tumours. In the 5 BD with moderate or heavy infiltrate, TH cells, TS/C cells and Leu-M5 positive cells did invade the tumour. In the tumour area where there was invasion, the number of LC was increased and HLA-DR was expressed on the cells. beta 2-microglobulin was generally expressed on the tumour cells of BD. We concluded that there is evidence for a T cell-mediated anti-tumour immune response which may account for the infrequent invasive growth in BD.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2500767     DOI: 10.1007/bf00784349

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  16 in total

1.  Characterization of the mononuclear infiltrate in basal cell carcinoma: a predominantly T cell-mediated immune response with minor participation of Leu-7+ (natural killer) cells and Leu-14+ (B) cells.

Authors:  J M Habets; B Tank; V D Vuzevski; E C van Reede; E Stolz; T van Joost
Journal:  J Invest Dermatol       Date:  1988-03       Impact factor: 8.551

2.  Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas.

Authors:  E Ralfkiaer; K Hou-Jensen; K C Gatter; K T Drzewiecki; D Y Mason
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

3.  Loss of beta2 microglobulin from the cell surface of cutaneous malignant and premalignant lesions.

Authors:  M L Turbitt; R M Mackie
Journal:  Br J Dermatol       Date:  1981-05       Impact factor: 9.302

4.  Dissociation of HLA heavy chain and light chain (beta 2 microglobulin) expression on the cell surface of cutaneous malignancies.

Authors:  G Mauduit; M Turbitt; R M MacKie
Journal:  Br J Dermatol       Date:  1983-10       Impact factor: 9.302

5.  HLA-DR antigen expression in primary melanomas of the skin.

Authors:  E B Bröcker; L Suter; C Sorg
Journal:  J Invest Dermatol       Date:  1984-03       Impact factor: 8.551

6.  Expression of human lymphocyte antigen (HLA)-DR on tumor cells in basal cell carcinoma.

Authors:  A Kohchiyama; D Oka; H Ueki
Journal:  J Am Acad Dermatol       Date:  1987-04       Impact factor: 11.527

7.  An absence of human leukocyte antigen-DR and a decreased expression of beta 2-microglobulin on tumor cells of basal cell carcinoma: no influence on the peritumoral immune infiltrate.

Authors:  J M Habets; B Tank; V D Vuzevski; E Stolz; T van Joost
Journal:  J Am Acad Dermatol       Date:  1989-01       Impact factor: 11.527

Review 8.  Natural killer cells: their roles in defenses against disease.

Authors:  R B Herberman; J R Ortaldo
Journal:  Science       Date:  1981-10-02       Impact factor: 47.728

9.  In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.

Authors:  S Poppema; E B Bröcker; L de Leij; D Terbrack; T Visscher; A Ter Haar; E Macher; T H Thé; C Sorg
Journal:  Clin Exp Immunol       Date:  1983-01       Impact factor: 4.330

10.  HLA and beta 2-microglobulin expression in basal and squamous cell carcinomas of the skin.

Authors:  L A Hua; C N Kagen; R J Carpenter; R W Goltz
Journal:  Int J Dermatol       Date:  1985-12       Impact factor: 2.736

View more
  1 in total

1.  Bowen's disease - a review of newer treatment options.

Authors:  Thorsten Neubert; Percy Lehmann
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.